Thursday, December 1-5, 2024 | McCormick Place Convention Center. 2301 S Martin Luther King Dr, Chicago, IL 60616
At the 2024 Radiological Society of North America (RSNA), a premier global radiology event that took place at McCormick Place in Chicago, Illinois, HeartLung Technologies presented four scientific research studies on AI innovations, including AI-CAC, AutoBMD, and AI-CVD. This conference highlighted the latest medical imaging and AI advancements, bringing together experts from various fields.
Additionally, Dr. Morteza Naghavi, MD, the founder of HeartLung Technologies and nonprofit SHAPE (Society for Heart Attack Prevention and Eradication), participated in one of the panel discussions hosted by Blackford, a pioneer in the radiology AI space, at the 2024 RSNA conference. With over a decade of experience, Blackford provides tailored solutions to unlock the value of AI, drive efficiencies, and improve patient outcomes.
How can AI enhance cardiovascular imaging?
The panel discussion at RSNA 2024 discussed AI's transformative impact on cardiovascular imaging. HeartLung.AI's Founder, President & CEO, Dr. Morteza Naghavi, MD, emphasized AI’s role in early or opportunistic detection and management of cardiovascular disease.
Watch the Panel Discussion Below:
Transcript of the Panel Discussion:
[Interviewer] [987.63s] I just saw doctor Morteza walk in.
[Interviewer] [990.51s] Thank you for taking some time to join us in this panel discussion.
[Interviewer] [994.67s] So we've been discussing about how AI, helps in the cardiovascular domain.
[Interviewer] [999.70s] So maybe a quick question to you.
[Interviewer] [1002.34s] So you, can you kind of give us give the audience a brief, insights on your solution and how it's helping the population health?
[Morteza Naghavi] [1012.75s] Sure.
[Morteza Naghavi] [1012.80s] Sorry.
[Morteza Naghavi] [1012.84s] I'm running late, Adrian.
[Morteza Naghavi] [1016.20s] I, I have to tell you that we are, pursuing a very ambitious goal to bring AI to the forefront of early detection of cardiovascular disease, both in the asymptomatic arena, which is like 80% of our population, and they're symptomatic.
[Morteza Naghavi] [1036.06s] So let's start with symptomatic, the easy one.
[Morteza Naghavi] [1038.96s] So patients come to emergency room in the US, about 12,000,000 with chest pain.
[Morteza Naghavi] [1045.05s] About 1 and a half to 2,000,000 actually are coronary disease cardiac patients.
[Morteza Naghavi] [1051.65s] Without AI, we're doing what we're doing today, which is keeping the rest of them all in the ER for 12 hours, 10 hours, do all kind of testing.
[Morteza Naghavi] [1061.49s] So we hope that AI will cut down that to less than 3 hours and let everybody else who is not high risk go home, you know, less than 3 hours.
[Morteza Naghavi] [1073.60s] That would be a major success and reduce a lot of costs, unnecessary costs.
[Morteza Naghavi] [1077.99s] So that's symptomatic.
[Morteza Naghavi] [1079.52s] And that that would be applying AI to coronary artery calcium scan, a regular non contrast.
[Morteza Naghavi] [1085.40s] If your CAC is 0 and your heart score is below 7, you should not be staying in the ER.
[Morteza Naghavi] [1091.96s] That's basically our our AI algorithm.
[Morteza Naghavi] [1094.92s] And we have data to support that.
[Morteza Naghavi] [1096.52s] And we're going to CMS, December 11th next week to talk to them about this.
[Morteza Naghavi] [1102.66s] The asymptomatic is the biggest pie, as you know.
[Morteza Naghavi] [1106.66s] So we have about 50 to 65,000,000 people following the intermediate risk category according to ACC guidelines, meaning we don't know exactly what to do with them.
[Morteza Naghavi] [1119.31s] The ones that are low risk, they don't need any treatment.
[Morteza Naghavi] [1123.23s] The one that are high risk need treatment.
[Morteza Naghavi] [1125.39s] But the 2, the low risk or higher score are less than 30%.
[Morteza Naghavi] [1128.41s] The rest of them are intermediate.
[Morteza Naghavi] [1130.89s] So applying AI enabled coronary artery calcium scan, not a score scan, allows you to take these bulk of intermediate and properly categorize them to low risk and high risk.
[Morteza Naghavi] [1148.75s] So the low risk is about half of them.
[Morteza Naghavi] [1150.67s] They don't need treatment.
[Morteza Naghavi] [1152.27s] The high risk is about half of them.
[Morteza Naghavi] [1154.03s] They need intensive treatment.
[Morteza Naghavi] [1156.38s] So our first step is coronary calcium scoring.
[Morteza Naghavi] [1160.38s] We have shown that AI can improve the power of 0.
[Morteza Naghavi] [1163.66s] Everybody who knows calcium score knows that a big value of calcium score is power of 0.
[Morteza Naghavi] [1169.11s] We have shown our AI can improve that, and it's a study sponsored by Mesa.
[Morteza Naghavi] [1174.81s] We also are able to see things that a physician cannot see, and that's cardiac chambers volume.
[Morteza Naghavi] [1180.09s] So we just got FDA breakthrough, designation and marketing authorization for what we call auto chamber.
[Morteza Naghavi] [1187.98s] So a non contrast chest CT scan, you can report cardiac chamber's volume.
[Morteza Naghavi] [1193.11s] And the Adrian and the team at Blackfords are preparing to introduce it to patient care.
[Morteza Naghavi] [1199.03s] Then you don't stop there.
[Morteza Naghavi] [1201.20s] Around the heart, there is bone density right behind the heart.
[Morteza Naghavi] [1205.20s] Our AI is also FDA approved.
[Morteza Naghavi] [1207.60s] We have just finished the same way, Nanox team did our, liver.
[Morteza Naghavi] [1213.45s] We have a slightly different approach for osteotosis.
[Morteza Naghavi] [1217.29s] We also found myoasteatosis, meaning fat droplet in the muscle is a highly predictive of future cardiovascular disease.
[Morteza Naghavi] [1226.75s] So in summary, there's an ocean of information hidden in a regular non contrast, you know, lowball chest CT scan that we can use with AI to advance health care.
[Interviewer] [1239.18s] That's really interesting.
[Interviewer] [1240.30s] Thank you for, the, answer and explaining to the audience how AI can help.
[Interviewer] [1245.27s] So we have, like, 2 more minutes remaining.
[Interviewer] [1247.74s] So I would like to ask the audience if there are any questions you would like to ask the panelists.
[Interviewer] [1257.82s] Okay.
[Interviewer] [1258.30s] If that's not the case, then we'd like to thank all the panelists for taking their time off and coming and talking to us and educating us on the role of AI in cardiovascular.
[Interviewer] [1267.26s] Thank you very much.
[Morteza Naghavi] [1268.22s] Thank you.
The panel discussions were hosted by Blackford at the 2024 Radiological Society of North America (RSNA 2024) in Chicago on December 1-5, 2024.
コメント